MA53014A - Composés améliorant l'activité du protéasome - Google Patents
Composés améliorant l'activité du protéasomeInfo
- Publication number
- MA53014A MA53014A MA053014A MA53014A MA53014A MA 53014 A MA53014 A MA 53014A MA 053014 A MA053014 A MA 053014A MA 53014 A MA53014 A MA 53014A MA 53014 A MA53014 A MA 53014A
- Authority
- MA
- Morocco
- Prior art keywords
- proteasome activity
- compounds improving
- improving proteasome
- compounds
- activity
- Prior art date
Links
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690563P | 2018-06-27 | 2018-06-27 | |
| US201862690565P | 2018-06-27 | 2018-06-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53014A true MA53014A (fr) | 2021-05-05 |
Family
ID=67439356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053014A MA53014A (fr) | 2018-06-27 | 2019-06-27 | Composés améliorant l'activité du protéasome |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11560385B2 (fr) |
| EP (1) | EP3814338A1 (fr) |
| JP (2) | JP7561632B2 (fr) |
| KR (1) | KR20210024588A (fr) |
| CN (1) | CN112585132B (fr) |
| AU (1) | AU2019295765B2 (fr) |
| BR (2) | BR112020026580A2 (fr) |
| CA (1) | CA3103954A1 (fr) |
| CL (1) | CL2020003380A1 (fr) |
| CR (1) | CR20200652A (fr) |
| IL (1) | IL279698A (fr) |
| MA (1) | MA53014A (fr) |
| MX (1) | MX2020014082A (fr) |
| PE (1) | PE20211804A1 (fr) |
| PH (1) | PH12020552261A1 (fr) |
| SG (1) | SG11202013026WA (fr) |
| WO (1) | WO2020006296A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20231253T1 (hr) | 2018-06-27 | 2024-02-02 | Bristol-Myers Squibb Company | Supstituirani spojevi naftiridina korisni kao aktivatori t stanica |
| HUE066335T2 (hu) | 2018-10-05 | 2024-07-28 | Annapurna Bio Inc | Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére |
| CN111423353B (zh) * | 2020-04-29 | 2022-03-22 | 湖北省生物农药工程研究中心 | 多取代n-芳基吡咯类化合物及其制备方法 |
| CN112142642B (zh) * | 2020-10-15 | 2022-03-04 | 华侨大学 | 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法 |
| WO2023107597A2 (fr) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Composés amides hétéroaromatiques bicycliques et leurs utilisations |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1142508A (en) | 1966-04-27 | 1969-02-12 | Whitefin Holding Sa | Pyrrole derivatives |
| GB1154745A (en) | 1966-05-17 | 1969-06-11 | Whitefin Holding Sa | Haloketones |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| CA2318263A1 (fr) | 1998-01-23 | 1999-07-29 | Angela Francisca Haczku | Methode de traitement des maladies inflammatoires utilisant des proteines du stress |
| US7842470B2 (en) | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| US20060148767A1 (en) | 2001-12-06 | 2006-07-06 | George Cioca | Use of acyl salicylates as heat shock inducers |
| BRPI0416216A (pt) | 2003-11-12 | 2006-12-26 | Amicus Therapeutics Inc | composto de glicoimidazol e polihidroxiciclohexenila e método para sintetizar composto de glicoimidazol e polihidroxiciclohexenila, métodos para inibir glicocerebrosidase, para aumentar a atividade de glicocerebrosidase e para estabilizar glicocerebrosidade, composição farmacêutica, métodos para inibir uma -glicosidade, e para tratar doença de gaucher, derivado de glicoimidazol e derivados de polihidroxiciclohexilamina |
| EP3782655A1 (fr) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés |
| WO2006133446A2 (fr) | 2005-06-08 | 2006-12-14 | Amicus Therapeutics, Inc. | Traitement de troubles du snc associes a des mutations dans des genes codant pour des enzymes lysosomales |
| US20070207992A1 (en) | 2006-02-21 | 2007-09-06 | Board Of Trustees Of Michigan State University | Geldanamycin derivatives and method of use thereof |
| US20070259820A1 (en) | 2006-05-03 | 2007-11-08 | The Regents Of The University Of Michigan | Methods and reagents for activating heat shock protein 70 |
| EP2533050B3 (fr) | 2006-05-16 | 2015-06-24 | Amicus Therapeutics, Inc. | Options de traitement pour la maladie de Fabry |
| DK1860101T3 (da) | 2006-05-24 | 2011-07-25 | Amicus Therapeutics Inc | Tartrat salt af isofagomin og fremgangsmåder til anvendelse deraf |
| JP5303458B2 (ja) | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| WO2008024978A2 (fr) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Dérivés de benzène, de pyridine et de pyridazine |
| KR101673621B1 (ko) | 2008-03-24 | 2016-11-07 | 노파르티스 아게 | 아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제 |
| US20130045992A1 (en) * | 2010-01-28 | 2013-02-21 | President And Fellows Of Harvard College | Compositions and Methods for Enhancing Proteasome Activity |
| WO2012154967A1 (fr) * | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Régulateurs de la protéostasie |
| US9849135B2 (en) * | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| EP3010899A1 (fr) | 2013-06-17 | 2016-04-27 | Lupin Limited | Dérivés de pyrrole utilisés comme modulateurs d'alpha-7-nachr |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015073528A1 (fr) * | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Composés renforçant l'activité des protéasomes |
-
2019
- 2019-06-27 MX MX2020014082A patent/MX2020014082A/es unknown
- 2019-06-27 MA MA053014A patent/MA53014A/fr unknown
- 2019-06-27 BR BR112020026580-2A patent/BR112020026580A2/pt unknown
- 2019-06-27 CN CN201980055152.2A patent/CN112585132B/zh active Active
- 2019-06-27 CR CR20200652A patent/CR20200652A/es unknown
- 2019-06-27 KR KR1020217002233A patent/KR20210024588A/ko not_active Ceased
- 2019-06-27 SG SG11202013026WA patent/SG11202013026WA/en unknown
- 2019-06-27 BR BR122023023216-0A patent/BR122023023216A2/pt unknown
- 2019-06-27 WO PCT/US2019/039600 patent/WO2020006296A1/fr not_active Ceased
- 2019-06-27 AU AU2019295765A patent/AU2019295765B2/en not_active Ceased
- 2019-06-27 JP JP2020573524A patent/JP7561632B2/ja active Active
- 2019-06-27 CA CA3103954A patent/CA3103954A1/fr active Pending
- 2019-06-27 PE PE2020002159A patent/PE20211804A1/es unknown
- 2019-06-27 EP EP19744945.7A patent/EP3814338A1/fr not_active Withdrawn
-
2020
- 2020-12-23 IL IL279698A patent/IL279698A/en unknown
- 2020-12-23 US US17/133,372 patent/US11560385B2/en active Active
- 2020-12-23 PH PH12020552261A patent/PH12020552261A1/en unknown
- 2020-12-23 CL CL2020003380A patent/CL2020003380A1/es unknown
-
2022
- 2022-11-18 US US18/057,020 patent/US12319698B2/en active Active
-
2024
- 2024-06-12 JP JP2024094936A patent/JP2024138260A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US11560385B2 (en) | 2023-01-24 |
| CN112585132B (zh) | 2025-02-28 |
| US20230183256A1 (en) | 2023-06-15 |
| JP2021529792A (ja) | 2021-11-04 |
| BR122023023216A2 (pt) | 2024-02-20 |
| IL279698A (en) | 2021-03-01 |
| JP7561632B2 (ja) | 2024-10-04 |
| PH12020552261A1 (en) | 2021-08-02 |
| AU2019295765A1 (en) | 2021-01-21 |
| MX2020014082A (es) | 2021-04-13 |
| CR20200652A (es) | 2021-04-28 |
| US20210115057A1 (en) | 2021-04-22 |
| CN112585132A (zh) | 2021-03-30 |
| WO2020006296A1 (fr) | 2020-01-02 |
| CL2020003380A1 (es) | 2021-05-14 |
| PE20211804A1 (es) | 2021-09-14 |
| BR112020026580A2 (pt) | 2021-03-23 |
| AU2019295765B2 (en) | 2024-08-29 |
| KR20210024588A (ko) | 2021-03-05 |
| US12319698B2 (en) | 2025-06-03 |
| EP3814338A1 (fr) | 2021-05-05 |
| JP2024138260A (ja) | 2024-10-08 |
| CA3103954A1 (fr) | 2020-01-02 |
| SG11202013026WA (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL292753A (en) | Compounds | |
| MA53172A (fr) | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| FR24C1022I2 (fr) | Modulation d'activité du complément | |
| EP3941898C0 (fr) | Composés fongicides | |
| MA52967A (fr) | Composés antagonistes du pcsk9 | |
| IL286833A (en) | Compositions containing brazzein | |
| IL289767A (en) | Novel heteroaryl-triazole compounds as pesticides | |
| MA53014A (fr) | Composés améliorant l'activité du protéasome | |
| EP3836923A4 (fr) | Composés pyrrolo-dipyridine | |
| MA52948A (fr) | Composés | |
| EP3737672A4 (fr) | Composés benzamide | |
| MA51669A (fr) | Composés | |
| MA53003A (fr) | Composés | |
| PT3774862T (pt) | Novos análogos de glp-1 | |
| EP3341498A4 (fr) | Interférence virtuelle de l'activité protéique par analyse d'enrichissement d'un régulon | |
| EP4045163A4 (fr) | Boîte d'activité | |
| EP4076492A4 (fr) | Composés antagonistes du pcsk | |
| IL282330A (en) | Therapeutic compounds | |
| EP3250230A4 (fr) | Modulateurs d'activité du complément | |
| EP4077318A4 (fr) | Composés | |
| EP3261631A4 (fr) | Inhibition de l'activité d'olig2 | |
| EP3833342A4 (fr) | Composés d'imidazotétrazine | |
| MA52946A (fr) | Composés | |
| IL281923A (en) | Compositions useful for treating gm1 gangliosidosis | |
| LT3867247T (lt) | Naujieji junginiai |